Physician profile
Lavanya Viswanathan
NPI 1982996708
$70,947.51
in general payments reported to CMS, 2019-2025
15 companies · $49K in 2025
The $49K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $23.59 · 2021: $30.19 · 2022: $255 · 2023: $566 · 2024: $20K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $15K · Travel and Lodging: $7,138 · Honoraria: $4,500 · Food and Beverage: $3,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,375.46 |
| Consulting Fee | $14,625.00 |
| Travel and Lodging | $7,137.83 |
| Honoraria | $4,500.00 |
| Food and Beverage | $3,554.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $64,076.62 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $5,170.44 | 2023-2025 | Sucraid |
| Abbvie INC. | $394.32 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.03 | 2019-2024 | Xifaxan, Trulance |
| Axonics, INC. | $139.52 | 2024 | Axonics |
| E.R. Squibb & Sons, L.L.C. | $130.55 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $124.40 | 2025 | Omvoh |
| Medtronic, INC. | $123.32 | 2025 | Manoscan |
| Gilead Sciences, INC. | $122.79 | 2019 | |
| Covidien Lp | $84.63 | 2019 | |
| Merck Sharp & Dohme LLC | $83.29 | 2019-2022 | |
| Mahana Therapeutics, INC. | $75.67 | 2022 | |
| Celgene Corporation | $74.66 | 2023 | Zeposia |
| Incyte Corporation | $25.19 | 2022 | |
| Organon LLC | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lavanya Viswanathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.